On Thursday, Shares of Array Biopharma Inc (NASDAQ:ARRY), added 3.38% and closed at $6.73 in the last trading session. The last trading range of the stock ranges between $6.53 and $6.96. Pierre Fabre recently declared first results from the pivotal Phase 3 COLUMBUS trial of binimetinib plus encorafenib (bini/enco) treatment in BRAF-mutant melanoma patients at the Society for Melanoma Research Annual Congress. The study met its primary endpoint, with the combination of bini/enco significantly improving progression free survival (PFS) contrast with vemurafenib, a BRAF inhibitor, alone. The combination of bini/enco was generally well-tolerated and stated adverse events (AEs) were overall consistent with previous published clinical trial results for the bini/enco combination in BRAF-mutant melanoma patients.
Anthera Pharmaceuticals Inc (NASDAQ:ANTH), dropped -31.65% and closed at $1.90 in the last trading session. The last trading range of the stock ranges between $1.72 and $2.34. The company’s Market capitalization is $90.08million with the total Outstanding Shares of 41.96 million.Anthera Pharmaceuticals, Inc. (ANTH) recently declared that the CHABLIS-SC1 clinical trial with blisibimod for the treatment of systemic lupus erythematosus (SLE) failed to meet its primary endpoint based upon the SLE Responder Index-6 (SRI-6) at 52 weeks. Although 47% of patients in the blisibimod arm as compared to 42% of patients in the placebo arm achieved this endpoint, the difference was not statistically significant. The SRI is a composite index comprised of SELENA-SLEDAI, BILAG and Physician Global Assessment criteria. A SRI-6 response requires a decrease of at least 6 points in SELENA-SLEDAI. The magnitude of blisibimod treatment effects for other SLE Response (SRI-4, and SRI-8) also did not achieve statistical significance.
Serum biological markers counting B-cells, immunoglobulins, and complement demonstrated statistically noteworthytreatment effects consistent with expectations and previous blisibimod clinical studies in lupus and IgA nephropathy. Adverse events between the blisibimod and placebo treatment arms were well balanced and blisibimod was generally well tolerated.